Top Suppliers:I want be here

  • DC Chemicals Limited
  • China
  • Product Name: ML261
  • Price: $800.0/100mg $1450.0/250mg $2900.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

902523-58-4

902523-58-4 structure
902523-58-4 structure
  • Name: ML-261
  • Chemical Name: 2-Chloro-N-[2-(3,4-diethoxyphenyl)ethyl]-4-methyl-4H-thieno[3,2-b ]pyrrole-5-carboxamide
  • CAS Number: 902523-58-4
  • Molecular Formula: C20H23ClN2O3S
  • Molecular Weight: 406.926
  • Catalog: Research Areas Inflammation/Immunology
  • Create Date: 2017-12-01 14:56:45
  • Modify Date: 2024-02-23 12:20:53
  • ML261 is a hepatic lipid droplets formation inhibitor with an IC50 value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation[1].

Name 2-Chloro-N-[2-(3,4-diethoxyphenyl)ethyl]-4-methyl-4H-thieno[3,2-b ]pyrrole-5-carboxamide
Synonyms 2-Chloro-N-[2-(3,4-diethoxyphenyl)ethyl]-4-methyl-4H-thieno[3,2-b]pyrrole-5-carboxamide
4H-Thieno[3,2-b]pyrrole-5-carboxamide, 2-chloro-N-[2-(3,4-diethoxyphenyl)ethyl]-4-methyl-
Description ML261 is a hepatic lipid droplets formation inhibitor with an IC50 value of 69.7 nM. ML261 can be used for the research of non-alcoholic fatty liver disease (NAFLD) and inflammation[1].
Related Catalog
Target

IC50: 69.7 nM (hepatic lipid droplets formation)[1]

In Vitro ML261 (1 nM-10 μM; 24 h) affects hepatic lipid droplets formation in murine AML-12 cells[1]. Cell Viability Assay[1] Cell Line: AML-12 cells Concentration: 1 nM-10 μM Incubation Time: 24 hours Result: Inhibited hepatic lipid droplets formation with an IC50 value of 69.7 nM.
References

[1]. Zou J, et al. Potent inhibitors of lipid droplet formation. 2014.

Density 1.3±0.1 g/cm3
Boiling Point 625.4±55.0 °C at 760 mmHg
Molecular Formula C20H23ClN2O3S
Molecular Weight 406.926
Flash Point 332.0±31.5 °C
Exact Mass 406.111786
PSA 84.22000
LogP 5.45
Vapour Pressure 0.0±1.8 mmHg at 25°C
Index of Refraction 1.610
Symbol GHS06
GHS06
Signal Word Danger
Hazard Statements H301
Precautionary Statements P301 + P310
RIDADR UN 2811 6.1 / PGIII